Compare MIND & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | TCRX |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 75.1M |
| IPO Year | N/A | 2021 |
| Metric | MIND | TCRX |
|---|---|---|
| Price | $4.74 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 116.7K | ★ 635.0K |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | $23.31 | N/A |
| Revenue Next Year | $1.01 | $19.81 |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $4.66 | $0.83 |
| 52 Week High | $14.50 | $2.57 |
| Indicator | MIND | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.71 | 57.66 |
| Support Level | N/A | $0.89 |
| Resistance Level | $6.89 | $1.16 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 10.19 | 81.35 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.